Abstract
The cell division cycle 25 (Cdc25) family of proteins is a group of highly conserved dual specificity phosphatases that regulate cyclin-dependent kinases and represent a group of attractive drug targets for anticancer therapies. To develop novel Cdc25B inhibitors, the ZINC database was screened for finding optimal fragments with de novo design approaches. As a result, top 11 compounds with higher binding affinities in flexible docking were obtained, which were derived from five novel scaffolds (scaffold C) consisting of the linker-part and two isolated scaffolds (scaffold A and B)located in the two binding domains (catalytic pocket and swimming pool), respectively. The subsequent molecular docking and molecular dynamics studies showed that these compounds not only adopt more favorable conformations but also have stronger binding interaction with receptor than the inhibitors identified previously. The additional absorption, distribution, metabolism, excretion and toxicity (ADMET) predictions also indicted that the 11 compounds (especially Comp#1) hold a high potential to be novel lead compounds for anticarcinogen. Consequently, the findings reported here may at least provide a new strategy or useful insights for designing effective Cdc25B inhibitors.
Keywords: ADMET, cancer, Cdc25B inhibitors, de novo design, drug design, molecular dynamics.
Combinatorial Chemistry & High Throughput Screening
Title:Design Novel Inhibitors for Treating Cancer by Targeting Cdc25B Catalytic Domain with De Novo Design
Volume: 17 Issue: 10
Author(s): Jing-Wei Wu, Huan Zhang, Yu-Qing Duan, Wei-Li Dong, Xian-Chao Cheng, Shu-Qing Wang and Run-Ling Wang
Affiliation:
Keywords: ADMET, cancer, Cdc25B inhibitors, de novo design, drug design, molecular dynamics.
Abstract: The cell division cycle 25 (Cdc25) family of proteins is a group of highly conserved dual specificity phosphatases that regulate cyclin-dependent kinases and represent a group of attractive drug targets for anticancer therapies. To develop novel Cdc25B inhibitors, the ZINC database was screened for finding optimal fragments with de novo design approaches. As a result, top 11 compounds with higher binding affinities in flexible docking were obtained, which were derived from five novel scaffolds (scaffold C) consisting of the linker-part and two isolated scaffolds (scaffold A and B)located in the two binding domains (catalytic pocket and swimming pool), respectively. The subsequent molecular docking and molecular dynamics studies showed that these compounds not only adopt more favorable conformations but also have stronger binding interaction with receptor than the inhibitors identified previously. The additional absorption, distribution, metabolism, excretion and toxicity (ADMET) predictions also indicted that the 11 compounds (especially Comp#1) hold a high potential to be novel lead compounds for anticarcinogen. Consequently, the findings reported here may at least provide a new strategy or useful insights for designing effective Cdc25B inhibitors.
Export Options
About this article
Cite this article as:
Wu Jing-Wei, Zhang Huan, Duan Yu-Qing, Dong Wei-Li, Cheng Xian-Chao, Wang Shu-Qing and Wang Run-Ling, Design Novel Inhibitors for Treating Cancer by Targeting Cdc25B Catalytic Domain with De Novo Design, Combinatorial Chemistry & High Throughput Screening 2014; 17 (10) . https://dx.doi.org/10.2174/1386207317666141029223505
DOI https://dx.doi.org/10.2174/1386207317666141029223505 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tachykinins and their Receptors in Human Malignancies
Current Drug Targets The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Strategies for the Synthesis of Hydroxamic Acids
Current Organic Synthesis Non-Pharmacological Interventions to Improve Health Status in COPD
Current Respiratory Medicine Reviews From Traditional European Medicine to Discovery of New Drug Candidates for the Treatment of Dementia and Alzheimer's Disease: Acetylcholinesterase Inhibitors
Current Medicinal Chemistry Nociceptin/Orphanin FQ Peptide Receptor as a Therapeutic Target for Obesity
Mini-Reviews in Medicinal Chemistry An Overview of Highly Optically Pure Chloramphenicol Bases: Applications and Modifications
Mini-Reviews in Medicinal Chemistry Possible Impact of Microglial Cells and the Monocyte-Macrophage System on Suicidal Behavior
CNS & Neurological Disorders - Drug Targets Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach
Current Medicinal Chemistry Synthesis and Study the Antimicrobial Activity of Novel 2-(1H-indol-3-yl)- N-(3, 4-diphenylthiazol-2(3H)-ylidene) Ethanamine Derivatives
Medicinal Chemistry Study on the Development of a Cyclohexane Based Tripodal Molecular Device as "OFF-ON-OFF" pH Sensor and Fluorescent Iron Sensor
Current Analytical Chemistry Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry “My Drink is Larger than Yours”? A Literature Review of Self-Defined Drink Sizes and Standard Drinks
Current Drug Abuse Reviews Major Depressive Disorder and Type II Diabetes Mellitus: Mechanisms Underlying Risk for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Amyloid-Related Biomarkers for Alzheimers Disease
Current Medicinal Chemistry